Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography

Gene Therapy

Volumn 6, Issue 4, 1999, Pages 606-615

  Asselin Paturel, C ^a   Lassau, N ^a,b   Guinebretiere J M ^c   Zhang, J ^b   Gay, F ^a   Bex, F ^b   Hallez, S ^b   Leclere, J ^b   Peronneau, P ^d   Mami Chouaib, F ^a   Chouaib, S ^a,c  

^a INSERM   (France)

^b Dept d'Imagerie Médicale ^*

^c INSTITUT GUSTAVE ROUSSY   (France)

^d EUROPEAN SPACE AGENCY   (France)

Author keywords

Angiogenesis; Doppler ultrasonography; Gene therapy; Interleukin 12; Semliki Forest virus vector

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; MESSENGER RNA; VIRUS VECTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOPPLER FLOWMETRY; GENE THERAPY; GENE TRANSFER; INTRATUMORAL DRUG ADMINISTRATION; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEMLIKI FOREST ALPHAVIRUS; SPLEEN CELL; TUMOR BLOOD FLOW; TUMOR REGRESSION; TUMOR VASCULARIZATION;

ANIMALS; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; INTERLEUKIN-12; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEMLIKI FOREST VIRUS; SPECIFIC PATHOGEN-FREE ORGANISMS; ULTRASONOGRAPHY, DOPPLER;

ALPHAVIRUS; ANIMALIA; MURINAE; RABBIT FIBROMA VIRUS; SEMLIKI FOREST VIRUS;

EID: 0032904888     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300841     Document Type: Article

References (49)

1. Colombo MP, Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 1994; 15: 48-51.
2. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes (review). Blood 1994; 84: 4008-4027.
3. Chouaib S et al. Interleukin-12 induces the differentiation of major histocompatibility complex class I-primed cytotoxic T-lymphocyte precursors into allospecific cytotoxic effectors. Proc Natl Acad Sci USA 1994; 91: 12659-12663.
4. Chua AO, Chizzonite R, Desai B. Expression cloning of a human IL-12 receptor component: a new member of the cytokine receptor superfamily with strong homology with gp130. J Immunol 1994; 153: 128-136.
5. Desai BB et al. The IL-12 receptor. II. Distribution and regulation of receptor expression. J Immunol 1992; 148: 3125-3132.
6. Manetti R et al. Natural killer cell stimulatory factor (interleukin12 [IL-12]) induces (Th1)-type specific immune responses and inhibits the development of IL-4 producing Th2 cells. J Exp Med 1993; 177: 1199-1204.
7. Chan SH et al. Induction of IFN gamma production by NK cell stimulatory factor (NKSF): characterization of the responder cells and synergy with other inducers. J Exp Med 1991; 173: 869-879.
8. Gately MK et al. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFNg in vivo. Int lmmunol 1994; 6: 157-167.
9. Brunda MJ et al. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J Exp Med 1993; 178: 1223-1230.
10. Bramson JL et al. Direct intratumoral injection of an adenovirus-expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther 1996; 7: 1995-2002.
11. Caruso M et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA 1996; 93: 11302-11306.
12. Tahara H et al. Effective eradication of established murine tumors with interleukin-12 (IL-12) gene therapy using a polycistronic retroviral vector. J Immunol 1995; 154: 6466-6474.
13. Colombo MP et al. Amount of interleukin-12 available at the tumor site is critical for tumor regression. Cancer Res 1996; 56: 2531-2534.
14. Tsung K et al. IL-12 induces T helper 1-directed antitumor response. J Immunol 1997; 158: 3359-3365.
15. Liljeström P, Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Bio/Technology 1991; 9: 1356-1361.
16. Liljestrom P. Alphavirus expression systems. Curr Opin Biotechnol 1994; 5: 495-500.
17. Mossman SP et al. Protection against lethal Simian immuno-deficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J Virol 1996; 70: 1953-1960.
18. Zhou X et al. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 1994; 12: 1510-1514.
19. Zhang J et al. Cloning of human IL-12 p40 and p35 DNA into the Semliki Forest virus vector: expression of IL-12 in human tumor cells. Gene Therapy 1997; 4: 367-374.
20. Folkman J. What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 1990; 82: 4-6.
21. O'Reilly MS et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med 1996; 2: 689-692.
22. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995; 1: 149-153.
23. Millauer B et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994; 367: 576-579.
24. Hori A et al. Suppression of solid tumor growth by immunoneu-tralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 1991; 51: 6180-6184.
25. Rak JW, Croix BDS, Kerbel RS. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 1995; 6: 3-18.
26. Voest EE et al. Inhibition of angiogenesis in vivo by interleukin-12. J Natl Cancer Inst 1995; 87: 581-586.
27. Bosari S et al. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992; 23: 755-761.
28. Cosgrove DO et al. Breast diseases: color Doppler US in differential diagnosis. Radiology 1993; 189: 99-104.
29. Lassau N et al. Value of high-frequency US for preoperative assessment of skin tumors. Radiographics 1997; 17: 1559-1565.
30. Lamer S et al. Radiologic assessment of intranodal vascularity in head and neck squamous cell carcinoma. Correlation with histologic vascular density. Invest Radial 1996; 31: 673-679.
31. Karlan BY, Platt LD. The current status of ultrasound and color Doppler imaging in screening for ovarian cancer. Gynecol Oncol 1994; 55: S28-S33.
32. Lee WJ et al. Breast cancer angiogenesis: a quantitative morphologic and Doppler imaging study. Ann Surg Oncol 1995; 2: 246-251.
33. Lassau N et al. Value of high frequency ultrasound and color Doppler ulstrasound for preoperative assessment of melanoma. American Roetgenology Society. 98th Annual Scientific Meeting. Am J Roentgenol 1998; 170: 197 (Abstr. 412).
34. Watanabe M et al. Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis. Am J Pathol 1997; 150: 1869-1880.
35. Kurjak A et al. An attempt to screen asymptomatic women for ovarian and endometrial cancer with transvaginal color and pulsed Doppler sonography. J Ultrasound Med 1994; 13: 295-301.
36. Mu J et al. Administration of recombinant interleukin-12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res 1995; 55: 4404-4408.
37. Rakhmilevich AL et al. Gene gun-mediated skin transfection with interleukin-12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 1996; 93: 6291-6296.
38. Yang Y et al. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
39. Zhou X et al. Generation of cytotoxic and humoral immune responses using non-replicative recombinant Semliki Forest virus. Proc Natl Acad Sci USA 1995; 92: 3009-3013.
40. Nastala CL et al. Recombinant interleukin-12 administration induces tumor regression in association with interferon-gamma and nitric oxide production. J Immunol 1994; 153: 1697-1706.
41. Rodolfo M et al. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. J Immunol 1996; 157: 5536-5542.
42. + tumor-infiltrating lymphocytes. J Exp Med 1991; 173: 647-658.
43. Schijns VE et al. IFN-gamma receptor-deficient mice generate antiviral Th1-characteristic cytokine profiles but altered antibody responses. J Immunol 1994; 153: 2029-2037.
44. Boehm U et al. Cellular responses to interferon-gamma. Annu Rev Immunol 1997; 15: 749-795.
45. Emoto M et al. Differences in the angiogenesis of benign and malignant ovarian tumors, demonstrated by analyses of color Doppler ultrasound, immunohistochemistry, and microvessel density. Cancer 1997; 80: 899-907.
46. Teruya-Feldstein J et al. The role of Mig, the monokine induced by interferon-gamma, and IP-10, the interferon-gamma-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. Blood 1997; 90: 4099-4105.
47. Fallarino F et al. Antigen-specific regression of established rumors induced by active immunization with irradiated IL-12-but not B7-1-transfected tumor cells. Int Immunol 1997; 9: 1259-1269.
48. Berglund P et al. Semliki Forest virus expression system: production of conditionally infectious recombinant particles. Biotechnology (NY) 1993; 11: 916-920.
49. Asselin-Paturel C et al. Failure of TGFbeta1 and IL-12 to regulate human FasL and mTNF alloreactive cytotoxic pathways. Tiss Antigen 1998; 51: 242-249.